 |
|
Indinavir |
| Systematic (IUPAC) name |
| 1-[2-hydroxy-4- [(2-hydroxy-2,3-dihydro- 1H-inden-1-yl) carbamoyl]-5-phenyl-pentyl]-4- (pyridin-3-ylmethyl)- N-tert-butyl-piperazine-2-carboxamide |
| Identifiers |
| CAS number |
150378-17-9 |
| ATC code |
J05AE02 |
| PubChem |
5362440 |
| DrugBank |
APRD00069 |
| Chemical data |
| Formula |
C36H47N5O4 |
| Mol. mass |
613.79 g/mol |
| Pharmacokinetic data |
| Bioavailability |
? |
| Protein binding |
60% |
| Metabolism |
Hepatic via CYP3A4 |
| Half life |
1.8 (± 0.4) hours |
| Excretion |
? |
| Therapeutic considerations |
| Licence data |
US |
| Pregnancy cat. |
C(US) |
| Legal status |
|
| Routes |
Oral |
Indinavir (IDV; trade name Crixivan, manufactured by Merck) is a protease inhibitor used as a component of highly active antiretroviral therapy (HAART) to treat HIV infection and AIDS.
History
The Food and Drug Administration (FDA) approved indinavir March 13, 1996, making it the eighth approved antiretroviral. Indinavir was much more powerful than any prior antiretroviral drug; using it with dual NRTIs set the standard for treatment of HIV/AIDS and raised the bar on design and introduction of subsequent antiretroviral drugs. Protease inhibitors changed the very nature of the AIDS epidemic from one of a terminal illness to a somewhat manageable one.
Increasingly, it is being replaced by newer drugs that are more convenient to take and less likely to promote resistant virus, such as lopinavir or atazanavir.
Administration
Unfortunately, indinavir wears off quickly after dosing and therefore requires dosing very precisely every eight hours in order to thwart HIV from forming drug resistant mutations including resistances to other protease inhibitors. It has restrictions on what sorts of food may be eaten concurrently.
Side effects
Side effects include
- Kidney stones
- Metabolic abnormalities including hyperlipidemia (cholesterol or triglyceride elevations)
- Bizarre alterations in body shape known as lipodystrophy
|
Merck & Co., Inc. |
|
| Corporate Directors: |
|
|
| Products: |
Alendronate · Aprepitant · Ertapenem · Ezetimibe · Ezetimibe/simvastatin · Finasteride · Fosaprepitant · Indinavir · Losartan · Lovastatin · Montelukast · Raltegravir · Rizatriptan · Rofecoxib · Simvastatin · Sitagliptin · Vorinostat |
|
| Publications: |
The Merck Index · The Merck Manual |
|
| Annual Revenue: $22.9 billion USD (▲2% FY 2004) · Employees: 63,000 · Stock Symbol: NYSE: MRK · Website: www.merck.com | |
|
Antivirals used against HIV (HAART) (primarily J05) |
|
Nucleoside & Nucleotide Reverse Transcriptase Inhibitors (NRTI) |
Abacavir (ABC)° • Dexelvucitabine§ • Emtricitabine° • Lamivudine (3TC)° • Tenofovir° • Didanosine • Zidovudine (AZT) • Apricitabine † • Stampidine † • Elvucitabine † • Racivir † • Amdoxovir † • Stavudine ‡ • Zalcitabine ‡ |
|
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI) |
|
|
| Protease Inhibitors (PI) |
Atazanavir° • Brecanavir§ • Fosamprenavir° • Lopinavir° • Darunavir • Nelfinavir • Ritonavir • Saquinavir • Tipranavir • Amprenavir‡ • Indinavir‡ |
|
| Entry/fusion inhibitors |
Aplaviroc§ • Enfuvirtide • Maraviroc • Vicriviroc† • PRO 140† • Ibalizumab† |
|
| Integrase inhibitors |
Raltegravir • Elvitegravir† |
|
| Maturation inhibitors |
Bevirimat† • Vivecon™† |
|
| Combined formulations |
Combivir • Atripla • Trizivir • Truvada • Kaletra • Epzicom |
|
Other & experimental agents |
Foscarnet • Hydroxyurea • Synergistic enhancers • Epigallocatechin gallate • Portmanteau inhibitors • Globoidnan A • Griffithsin • Diarylpyrimidines • Calanolide A • Cyanovirin-N • Miltefosine • R-roscovitine† |
|
°DHHS preferred first-line agent. †Undergoing clinical trials, not FDA approved. ‡Formerly or rarely used agent. §Development terminated. | |
Source: adapted by the editor from Wikipedia, the free encyclopedia; from the article "Indinavir". Image Credit.